List of Koselugo drug patents
Koselugo is owned by Astrazeneca.
Koselugo contains Selumetinib Sulfate.
Koselugo has a total of 4 drug patents out of which 0 drug patents have expired.
Koselugo was authorised for market use on 10 April, 2020.
Koselugo is available in capsule;oral dosage forms.
Koselugo can be used as treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).
Drug patent challenges can be filed against Koselugo from April, 2024.
The generics of Koselugo are possible to be released after 10 April, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(a month from now) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Apr, 2024
(1 year, 2 months from now) | |
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(3 years from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic